Index

added value 29, 30-31, 52, 137, 145, 146, 148
see also synergies
agency problems 68, 70, 73, 75
Ahuja, G. 2, 48, 50, 52, 54, 59–60, 61, 87, 89, 136, 161
AirTouch Communications, Inc 23
Alcatel 23–4
alliances 16, 17, 22, 150, 162–4, 165
anti-trust authorities 164–5
anti-trust laws 11, 12
Arrow, K.J. 161
Asian M&As 14, 15
automotive sector 13
bank loans 27
banking sector 18, 32, 33
bankruptcy 43, 46, 55
bargaining power 40
BASF and Solvay merger case study
see Solvay and BASF merger case study
Belgium see Solvay and BASF merger case study
bidder corporate control 25–6
biotechnology sector 16, 146, 148, 149, 154
Bittlingmayer, G. 14
Bourgeois, L.J 79
Bresman, H. 51
Britain see United Kingdom broadband technologies 23–4
bureaucracy 68, 69–70, 72–3, 75, 85, 86
business culture 49, 138
business cycles 16, 19
business services sector 20
Canada 26, 136
Cantwell, J.A. 16–17, 33, 36
capabilities see complementary technological capabilities; location-specific capabilities;
management capabilities; R&D capabilities
capital markets 12, 38–9, 43, 69, 73
Capron, L. 49, 50, 57
case study designs 8, 54, 58–9, 77–8, 79–81, 124, 159
Chakrabarti, A. 50, 52–3, 54, 58–9, 61
champions, innovation 50, 163, 164
Chatterjee, S. 52
Chaudhuri, S. 49
chemicals and pharmaceutical sectors 20, 21, 22, 32–3, 34–5, 52, 59–60, 134–5
see also DSM acquisition of Gist-brocades case study; Henkel acquisition of Novamax case study; Pharmacia & Upjohn and Monsanto merger case study; Solvay and BASF merger case study
Chevalier, J.A. 52
collaboration 51, 108, 152, 154
see also alliances; joint ventures; manufacturer-supplier relationships; networks; prior relationships
commercialization 72, 73, 153
communications 31, 33, 41, 51, 162
competences see complementary technological field (CTF) firms; new technological competences; same technological field (STF) firms; technological competences
competition 22, 32, 34, 35, 135, 136, 137, 138
see also non-rival firms; rival firms; technological competition
competition motivated M&As 29, 42–3, 140, 142–3, 144–5
competitive advantage 21, 22, 29, 33, 135
complementary culture 136, 140

189
complementary products 135, 137, 145, 147, 151
complementary technological
capabilities 29, 30–31, 33, 34, 35, 61
complementary technological field
(CTF) firms
policy implications 164–5
R&D personnel 2, 139, 140, 150–51, 160
in R&D process empirical study
M&A classification 82, 83–4, 85, 86
in M&A sample 97, 98–9
effect of market relatedness 108, 115–16
resource redeployment 85, 116, 117
technological competences 85, 115, 117
see also DSM acquisition of Gist-brocades case study; Henkel acquisition of Novamax case study; Pharmacia & Upjohn and Monsanto merger case study
construct validity 79–80
cost savings 31, 33, 50, 148, 149
costs 32, 33, 162
see also fixed cost spreading; R&D costs; social costs; transaction cost reductions
cross-border competitiveness 135
cross-border intra-firm networks 16–17
cross-border M&As
absorptive capacity 33
bureaucracy 86
competitiveness 29
cultural differences 86, 162
EU 19, 25, 26
and global competitiveness 29
local skills and expertise 31
market motivated 22
in merger waves 12, 13
pharmaceuticals sector 34–5
rationalization 86
in R&D process empirical study 83–4, 86–7, 108, 109, 119–21
and regulations 22
resource redeployment 86–7
restructuring motivated 31
telecommunications sector 22–3
trends 13–16
cross-border MNE networks 16–17
cultural distance 53, 86, 150–51, 162
culture 49, 50, 68, 136, 138, 140, 146, 150–51
customers 22, 32, 142, 144, 147, 151, 154
cutbacks 29, 69, 71, 74, 139, 140, 142–3, 146
Daimler Chrysler merger 13
De Jong, H.W. 25
debt 43, 45, 46, 55, 61
defensive reactions 30, 136–8
deregulation 17, 22–3, 30
development 85, 117, 139, 144, 153, 156
diseconomies of R&D 41, 49, 68, 72–3
distribution networks 21
diversification 12, 29, 36, 42, 67, 72
see also technological diversification
domestic M&As 14, 18, 86–7, 99, 108, 109, 119–21
downsizing 29, 139, 142–3
see also cutbacks; rationalization; R&D rationalization; R&D restructuring
DSM acquisition of Gist-brocades case study
discussion 151–2
introduction 135, 145–6
potential fit 146–9
success 149–51
duplication elimination 41, 67, 69, 71, 74, 82, 85
see also cutbacks; downsizing;
rationalization; R&D rationalization; R&D restructuring
Duysters, G. 53
Eastern Europe 25
economic growth 11, 12
economies of scale
and M&A motivations 37, 52, 161
effect of M&As on R&D ex post 41, 42, 47, 48
effect of M&As on R&D process 36, 65, 66, 71, 82
and prior relationships 87
production effects of M&As on R&D process 69, 73, 85
in the same technological field (STF) firms 160
economies of scope complementary technological capabilities 35
and M&A motivations 35, 37, 52, 161
effect of M&As on R&D ex post 42, 47, 48
effect of M&As on R&D process 66–7, 71, 82
and prior relationships 87
production effects of M&As on R&D process 69, 74, 85
and technological relatedness 30–31
efficiency 18, 22, 31, 33, 37, 46, 55
see also cutbacks; diseconomies of R&D; downsizing; duplication elimination; economies of scale; economies of scope; fixed cost spreading; inefficiencies; rationalization; R&D restructuring; restructuring
Eisenhardt, K.M. 78, 79
employee motivation see motivation, employee employment


cutbacks 29, 74, 139, 140, 143
growth 140, 145, 150
effect of LBOs on R&D intensity ex post 46, 55
effect of M&As on R&D ex post 41
production process effects on R&D process 70, 74, 75
Ericsson 24
Ernst, H. 2, 49, 50–51, 53, 160
Euro-zone countries 27
Europe 12, 13, 14–16, 17, 23–4, 25, 134–5, 154, 164
see also France; Germany; Ireland; Netherlands; Norway; Sweden; Switzerland; United Kingdom

Europe Commission 134–5, 147–8
European Single Market 17
European Union 16, 18–27, 50–51
external validity 80

Faccio, M. 25
fifth M&A wave

driving factors 1–2, 16–18
European trends 18–27
global trends 12, 13–16
transport and communications cost reductions 33
finance 32, 37, 38–9, 41, 45, 69, 70, 73, 75
financial markets 11, 30, 70, 75
financial synergies 52
financing instruments 18
firms 16, 18, 33, 47, 50, 53
see also complementary technological field (CTF) firms; large firms; local firms; MNEs; new technology based firms (NTBFs); non-rival firms; rival firms; same technological field (STF) firms; small firms
fixed cost spreading 65, 66–7, 69, 71, 73
flexibility 18, 22, 33, 41
food industry 20, 21
Fore Systems 24
foreign investment 21, 32
France 23–4
Franks, J.R. 25

GDP 24–5
General Electric Co. 24
General Motors (GM) 18
geographic scope 83–4, 86–7, 99, 108–9, 119–21, 162
geographical markets 32, 135, 137, 140, 142, 152, 154
Germany 24, 25
see also Henkel acquisition of Novamax case study
Gist-brocades acquisition by DSM case study see DSM acquisition of Gist-brocades case study
globalization 17
Gort, M. 47, 48
Granstrand, O. 50, 51, 54, 58
Hagedoorn, J. 53
Hall, B.H. 2, 45, 47, 53, 55–6, 89
healthcare sector 16
Henkel acquisition of Novamax case study
acquirer, target and motives for deal 137–8
discussion 140
introduction 135, 136–7
market rivals 135
post-deal 138–40, 163
high-tech industries 16, 17, 21, 48, 161, 164
high-tech products 17
Hitt, M.A. 2, 41, 45, 53, 56, 89
hold-up problem 39
horizontal M&As 11, 22, 52, 89, 97, 161
hostile takeovers 12, 25
imitation 34, 118
in-house R&D 32
see also R&D departments; R&D facilities; R&D personnel; R&D teams
incentives 41, 49
indivisibilities 65, 66–7, 69, 71, 73, 74, 82
industrial sector 16, 20
inefficiencies 38–9, 40
information 31, 49, 162, 163–4, 165
see also knowledge; learning
Information and Communications Technologies (ICTs) 22, 23–4, 31, 33, 35–6, 53
innovation see R&D
innovation champions 50, 163, 164
innovative cultural differences 50–51
innovative culture 50, 68
intangible assets 21, 33
internal validity 80
international see cross-border
Internet sector 22, 23–4
intra-industry M&A 32, 34
inventors 50–51, 53
investment see foreign investment; R&D investment
investment banks 18
Ireland 25
Japan 26
Johansson, S. 22, 23–4, 34
joint ventures 136, 141, 144, 145, 146, 151, 163
junk bonds 12, 18
Kang, N.-H. 22, 23–4, 34
Katila, R. 2, 48, 50, 52, 54, 59–60, 61, 87, 89, 136, 161
know-how 17, 42, 49–50, 51–2, 61, 66, 67, 148, 149
knowledge
and complementary technological competences 33, 117–18
and cross-border M&As 21, 33
impact of M&As on R&D ex post 148
and prior relationships 17, 87, 162–3, 164
relatedness 51–2, 54, 59, 117–18
in same technological competence (STC) firms 117–18, 143, 145
transfer 150–51
see also information; know-how; learning; local knowledge; local skills; tacit knowledge; technological knowledge
knowledge spillovers 33, 66–7, 71, 120, 122, 139
knowledge synergies 29, 51–2, 67, 72, 161–2
Kodama, F. 35
large firms 47, 50, 51
laws, anti-trust 11, 12
learning 49, 51
Lee, J. 135
leveraged buyouts (LBOs) 12, 46, 55–6
liberalization 30, 31
Lichtenberg, F. 46
local firms 21
local knowledge 21, 35
local skills 31, 33
location-specific capabilities 17
Long, W. 46
M&As (mergers and acquisitions)
anti-takeover provisions 40
Index

classification 81–7
cross-border see cross-border M&As
domestic see domestic M&As
by global sectors 16
intensity 20–21, 29
merger waves 11–13
see also fifth M&A wave
motivations 30–33, 36, 37, 38, 52,
135–6, 161
post-deal strategies 49
pre-deal strategies 49
trends (1985-2003) 13–16
management 18, 25, 150–51
see also managers; organizational
structures; top management
management capabilities 33
managers 30, 39, 40, 61
Manchin, M. 27
Mannesman 13
manufacturer-supplier relationships 137
manufacturing sector 19, 20, 21, 45,
47–8, 55–6, 57
market motivated M&As
cross-border 22
financial synergies 52
intra-industry 32, 34
pre-deal relatedness 32
in R&D process empirical study
83–4, 87, 100–102, 122, 123
and R&D restructuring 123
and technology market power 34
compared to technology motivated
M&As 87, 161
market power
and deregulation 30
horizontal M&As 52, 161, 164
M&A motivations 30, 31–2, 33, 37
effect of M&As on R&D ex post 42,
47
effect of M&As on R&D process 68,
72, 85
and restructuring 34
and technology 34, 82
market relatedness
in M&A integration processes 51,
52, 53
measurement 52, 53
R&D process empirical study
M&A classification 83–4, 85, 86
M&A sample 97, 98

effect on R&D inputs and
performance 107–8
effect on synthetic indicators
115–16, 118–19, 126–33
see also DSM acquisition of Gist-
brocades case study; Henkel
acquisition of Novamax case
study; Pharmacia & Upjohn
and Monsanto merger case
study; Solvay and BASF merger
case study
market share 138, 140, 161
marketing 152, 154
markets
concentration 47
and defensive reactions 30, 136–8
integration 19
and M&A motivations 30, 31–2
effect of M&As on R&D ex post
42–3
and political power 30
production process effects on R&D
process 69, 73
size 47
and technological change 22
Masulis, R. W. 25
Mayer, C. 25
media sector 16, 22
methodologies
empirical studies linking M&A to
R&D 7–8, 53–61, 159
R&D intensity 47, 48, 54, 56, 60, 61,
159
R&D process empirical study 8,
77–81, 105–6, 109–11, 112–14,
124, 159–60, 165, 167–79
relatedness measurement 52, 53,
59–60
MNEs 16–17, 29
mobile communications sector 22, 23
Molson Group 156–7
monopoly power 42–3
Monsanto and Pharmacia & Upjohn
merger case study see Pharmacia
& Upjohn and Monsanto merger
case study
motivation, employee
effect of M&As on personnel 36
effect of M&As on R&D personnel
68, 73, 85, 144, 163
effect of prior relationships 162
production process effects on R&D personnel 70, 75
in same technological field (STF) firms 85, 113, 117, 163
motivations, M&A 30–33, 36, 37, 38, 135–6
see also competition motivated M&As; market motivated M&As; non-technology motivated M&As; technology motivated M&As

national regulations 22
Netherlands 24, 25
see also DSM acquisition of Gist-brocades case study
networks 16–17, 21, 35
new business opportunities 30, 32, 34
new markets 30, 32, 33, 34
new production processes 118
new products 32, 34, 138–9, 148, 149, 153, 156
new technological competences 117, 118, 119, 161
new technologies 22, 30, 153, 162
new technology based firms (NTBFs) 50, 51, 58
non-core activities 18
non-rival firms
in R&D process empirical study
complementary technological field (CTF) firms 6, 106, 107, 115–16, 117
effect of market relatedness 107, 108, 115–16, 118–19
same technological field (STF) firms 6, 106, 107, 115–16, 117
sample 6, 97, 98
effect of technological-relatedness 106–7
see also DSM acquisition of Gist-brocades case study; Solvay and BASF merger case study
non-technology motivated M&As 34, 48, 59, 64–5, 109, 161
Norway 24, 26
Novamex acquisition by Henkel case study see Henkel acquisition of Novamex case study

OLI (Ownership, Location, Internalization) paradigm 33
oligopolies 11, 161
organizational change 138, 145–6, 163 see also technological change
organizational structures 18, 49, 68, 72–3, 85, 86, 143–5
see also management; R&D organization
outsourcing 18, 150, 156

patents
effect of market relatedness 118
as measure of R&D intensity 47, 48, 54, 56, 60, 61, 159
as measure of technological relatedness 52, 53, 60
payment methods 25–6
personnel see employment; inventors; management; managers;
motivation, employee; R&D departments; R&D personnel;
R&D teams; top management
pharmaceutical sector see chemicals and pharmaceutical sectors
Pharmacia & Upjohn and Monsanto merger case study
deal description and motivation 153–4
discussion 156
introduction 135, 152–3
effect on technological performance 154–6
Philips Electronic NV 24
political power 30, 32
post sector 23
power see bargaining power; market power; monopoly power; political power; technology market power
prior relationships
in DSM acquisition of Gist-brocades case study 145, 146, 151
economies of scale 87
economies of scope 87
and knowledge 87, 162–3, 164
and R&D integration 162
in R&D process empirical study 83–4, 87, 99–100, 108, 110
and restructuring 87
and technological competences 87
see also alliances; collaboration;
joint ventures; manufacturer-
supplier relationships; networks
privatization 30, 31
product life-cycles 17, 22, 135, 138–9,
140
see also time horizons
product specialization 135, 141, 142,
144
production inputs 64
production know-how 148, 149
production outputs 64, 65, 66
production plant closures 139, 142–3, 146
production process 64–5, 69–70, 73, 74,
75, 85
production specialization 69, 73, 74, 85
products 138–9, 140, 146–7, 148
see also complementary products;
high-tech products; new
products; product life-cycles;
product specialization; same
products
profitability 135, 143, 149
rationalization 31, 34, 36, 146, 148
see also cutbacks; downsizing; R&D
rationalization; R&D
restructuring; restructuring
Ravenscraft, D.J. 2, 45, 46, 53, 55, 89
R&D
and competition 42–3
downsizing 29, 139, 142
and foreign investment 32
international MNE networks 16–17
and market power 42, 47, 68, 72, 85
effects of M&As on long-term
performance 29, 39
effects of M&As on short-term
performance 29, 32, 39
see also development
R&D capabilities 42, 50, 57, 65, 66–7,
71
R&D costs 17, 22, 32–3, 148, 155
R&D departments
in DSM acquisition of Gist-
brocades case study 148
effect of M&A on R&D process 67, 72
in Pharmacia & Upjohn and
Monsanto merger case study
155, 156
in R&D integration processes 51, 53
in Solvay and BASF merger case
study 143, 144, 145
R&D efficiency 41, 143, 161
R&D effort 32, 111, 115, 118, 122, 123,
144
R&D expenditures 114, 150, 152, 156,
159
see also R&D intensity; R&D
performance
R&D facilities
in DSM acquisition of Gist-
brocades case study 150, 151
in Henkel acquisition of Novamax
case study 139
effect of market relatedness 118
in R&D process empirical study 106,
107, 108–9, 110, 111, 112
in Solvay and BASF merger case
study 142, 145
see also resource redeployment
R&D funding
in complementary technological field
(CTF) firms 155, 156
and Information and
Communications Technologies
(ICTs) costs 33
effect of LBOs on R&D intensity ex
post 46, 55
effect of M&As on R&D ex ante 38-
39, 40
effect of M&As on R&D process 68,
69, 73, 74
and production process effects on
R&D process 70, 75
effect of technological relatedness
114, 150, 151
R&D inputs
and bureaucracy and internal
structure 68, 70, 72, 75
description 63, 64
in DSM acquisition of Gist-
brocades case study 148
and economies of scale in
production 69, 73
and economies of scope in
production 69, 74
elimination of duplication in R&D
41, 67, 71
effect of geographic scope 108, 109, 119, 120
indicators 105–6, 110, 112
indivisibilities/specialization in R&D
quantity 65, 66, 71
indivisibilities/specialization in R&D
types 66–7, 71
effect of M&A motivations 108–9, 111, 122, 123
effect of market relatedness 107–8, 115, 118, 126–7
effect of prior relationships 108, 110, 120
in R&D process empirical study 108, 110, 119
synergies 67, 69, 71–2, 74
see also knowledge; R&D
capabilities; R&D expenditures;
R&D facilities; R&D funding;
R&D investment; R&D personnel
R&D integration process 49–53, 57–8, 162, 163
R&D intensity
in chemicals and pharmaceutical
sector 135, 138, 143, 155–6
in European sectors 20–21
and firm size 47
effect of M&As on R&D ex ante 38–40
effect of M&As on R&D ex post
critical assessment of empirical
evidence 53–4, 61
empirical evidence 44–5, 47–53, 55–60
theories 40–44
effect on M&As 1–2, 47–8
measurement 47, 48, 53–4, 55, 56, 61, 159
R&D investment 40, 42, 43, 66, 67, 135, 148, 156
R&D mission
in DSM acquisition of Gist-brocedes case study 150, 151
effect of geographic scope 121
indicators 110, 114
effect of M&A motivations 122
effect of market relatedness 116, 118–19, 133
effect of prior relationships 121
effect of technological relatedness 114, 116, 117, 133
R&D motivated M&As see technology
motivated M&As
R&D organization
effect of geographic scope 120–21
indicators 110, 113–14
effect of M&A motivations 122, 123
effect of market relatedness 115–16, 118–19, 131–2
effect of prior relationships 120–21, 122
effect of technological relatedness 115–16, 117, 131–2, 150, 151
R&D outputs
and bureaucracy and internal
structure 68, 70, 72, 75
description 63–4
effect of geographic scope 120
indicators 110, 112–13
indivisibilities/specialization in
production quantity 69, 74
indivisibilities/specialization in R&D
quantity 65, 66, 71
indivisibilities/specialization in R&D
types 66–7, 71
effect of M&A motivations 48, 122, 123
effect of market relatedness 53, 115, 118, 128–9
effect of prior relationships 120, 122
in R&D integration processes 50–51, 53
and synergies in R&D 67, 71–2
effect of technological relatedness 53, 115, 117, 119, 128–9
R&D outsourcing 45, 150, 156
R&D performance
and bureaucracy and internal
structure 68, 70, 72, 75
in complementary technological field
(CTF) firms 2, 138, 140, 155
defined 64
elimination of duplication in R&D
67, 71, 74, 82, 85

Bruno Cassiman and Massimo G. Colombo - 9781847201584
Downloaded from Elgar Online at 03/22/2022 10:47:33AM
via free access
Index

effect of geographic scope 107–8, 109, 120
indicators 105–6, 110, 113
indivisibilities/specialization in production quantity 69, 74
indivisibilities/specialization in R&D quantity 65, 66, 71
indivisibilities/specialization in R&D types 66–7, 71
effect of M&A motivations 34, 108–9, 111, 122, 123, 135–6, 161 and market power 68, 72
effect of market relatedness 107–8, 115, 118, 130
effect of prior relationships 108, 110, 120, 122
rival firms 161
in same technological field (STF) firms 85, 119, 130, 144–5, 160, 163
synergies in R&D 67, 71–2
R&D personnel
in complementary technological field (CTF) firms 2, 139, 140, 150–51, 160
and economies of scale and scope 32, 48
effect of firm-level motivation 108–9, 111
effect of geographic scope 109, 119
in large diversified firms 47
effect of M&A on R&D process 66, 67
effect of market relatedness 107, 118, 162
effect of prior relationships 108, 110
in R&D integration processes 49, 51, 58, 61, 162
in same technological field (STF) firms 85, 106, 107, 143, 144, 145, 160, 163
effect of technological relatedness 106, 107, 114
see also inventors; motivation, employee; R&D departments; R&D teams
R&D process empirical study
bureaucracy and internal organization 68, 69–70, 72–3, 75, 85
conclusions 123–4
elimination of duplication in production 69, 74, 82
elimination of duplication in R&D 47, 67, 71, 82
indivisibilities/specialization in production quantity 69, 73
indivisibilities/specialization in production type 69, 74
indivisibilities/specialization in R&D quantity 65, 66, 71, 82
indivisibilities/specialization in R&D type 66–7, 71
M&A classification 81–7
M&A sample 89–90
construction 90–91
geographic scope and pre-merger relationship 99–100
motivations 100–102
relatedness 92, 97–9
size and stratification 91–2, 93–6
and market power 68, 69, 72, 74, 82
research design and methodology 8, 77–81, 105–6, 109–11, 112–14, 124, 159–60, 165, 167–79
results
effect of geographic scope 108, 109, 119–21
effect of M&A motivations 108–9, 111, 122, 123
effect of market relatedness 107–8, 115–16, 118–19, 126–33
effect of prior relationships 108, 110
synergies in R&D 67, 71–2, 82
R&D projects 114, 117, 118, 139–40, 144, 150, 156
R&D rationalization
cross-border M&As 86
and diversification 36
effect of geographic scope 119, 120
in Henkel acquisition of Novamax case study 138
Index

long-term 29
in Solvay and BASF merger case
study 143, 144–5, 163
effect of technological relatedness
114, 117, 119, 160
short-term 29
R&D resources 32–33
see also R&D expenditures; R&D
facilities; R&D funding; R&D
inputs; R&D investment; R&D
personnel
R&D restructuring
in complementary technological field
(CTF) firms 155, 156
in cross-border M&As 86–7
elimination of duplication 67, 71
in market-motivated M&As 122, 123
effect of prior relationships 87, 121,
122
effect of technological relatedness
117, 143, 144–5
R&D specialization 41, 65–7, 71, 115,
117, 152, 155, 156
R&D teams 66, 67, 139, 144, 150
regulations 30
see also deregulation; liberalization
relatedness 29, 32, 51–3, 54, 59–60
see also DSM acquisition of Gist-
brocades case study; Henkel
acquisition of Novamax case
study; market relatedness;
Pharmacia & Upjohn and
Monsanto merger case study;
R&D process empirical study;
Solvay and BASF merger case
study; technological relatedness
reliability 80
resource redeployment
in complementary technological field
(CTF) firms 85, 106, 116, 117
cost savings 50
cross-border M&As 86–7
effect of geographic scope 119, 120
in R&D integration processes 49, 50,
57, 66, 67, 71
effect of technological relatedness
106, 107
restructuring 30, 31, 34–5, 135, 139,
140
see also R&D restructuring
risk reduction 43, 45, 163
risk-sharing 22, 32
risk-spreading 67, 72
risk-taking 139
rival firms
market power 161, 164
R&D performance 161
in R&D process empirical study 6,
97, 98, 107, 108, 115–16,
118–19, 123
see also Henkel acquisition of
Novamax case study
Rumelt, R. 51
sales 138–9, 140, 149, 152, 154, 155,
156, 163
same products 135, 137
same technological field (STF) firms
bureaucracy and internal
organization 85, 163
development 85
in innovation process empirical
study
M&A classification 82, 83–4, 85,
86
M&A sample 6, 97, 98–9
effect of market relatedness 6, 107,
108, 115–16, 118–19
effect of technological relatedness
6, 106, 107, 108, 111,
114–18
motivation, employee 85, 113, 117
motivations, firm-level 34
policy implications 164
R&D performance 85, 119, 130,
144–5, 160
R&D personnel 85, 106, 107, 143,
144, 145, 160, 163
technological competences 115,
118
see also Solvay and BASF merger
case study
Santangelo, G.D. 35, 36
Scherer, F.M. 2, 45, 46, 53, 55, 89
sectors 19–24, 29
see also automotive sector; banking
sector; biotechnology sector;
business services sector;
chemicals and pharmaceutical
sectors; food industry;
healthcare sector; high-tech industries; industrial sector; Information and Communications Technologies (ICTs); Internet sector; manufacturing sector; media sector; mobile communications sector; post sector; service sectors; technology sector; telecommunications sector

service sectors 19, 20, 32, 33
share swap restrictions 25
shareholders 39
Shleifer, A. 40
short-termism 32, 39, 41, 160
Sjölander, S. 50, 51, 54, 58
small firms 11, 12, 41, 50, 51, 58
social costs 40
Solvay and BASF merger case study
deal 141–3
discussion 144–5
introduction 135, 140–41
effects of merger 143–4, 163
specialization see product specialization; production specialization; R&D specialization
spillovers see knowledge spillovers; technological spillovers
stock market bubbles 13
strategic control 41, 45
surveys 54, 57, 61
Sweden 24, 51, 58
see also Pharmacia & Upjohn and Monsanto merger case study
Switzerland 25, 26
synergies
and asset relatedness 29
in cross-border M&As 36
in Henkel acquisition of Novamax case study 137
effect of M&A on R&D process 67, 71–2, 82
effect of market relatedness 115, 118
in Pharmacia & Upjohn and Monsanto merger case study 152, 155–6
production process effects on R&D process 69, 74
effect of technological relatedness 30–31, 161
see also added value; financial synergies; knowledge synergies; technological synergies
Tabrizi, B. 49
tacit knowledge 29, 51, 143
technical communications 51
technical learning 51
technological change 1, 20–24, 30–31, 32–3, 34, 135
technological competences 85, 87, 115, 117, 118
technological competition 115, 117–18, 119, 164
technological distance 51, 53
technological diversification 117
technological fusion 35–6
technological knowledge 115, 117–18
technological opportunity 47
technological relatedness
and M&A motivations 30, 33, 34
measurement 52, 53, 59–60
in R&D integration processes 51, 52–3
R&D process empirical study
M&A classification 82–5
M&A sample 97, 98
effect on R&D inputs and performance 106–7, 108, 160
effect on R&D synthetic indicators 111, 114–18, 119, 126–33, 160
and technological competition 115, 117–18, 119, 164
technology motivated M&As 34, 52–3, 59–60
transaction cost reduction 31
see also DSM acquisition of Gistbrocades case study; Henkel acquisition of Novamax case study; Pharmacia & Upjohn and Monsanto merger case study; Solvay and BASF merger case study

technological spillovers 42
technological synergies 48, 148, 161
technological uncertainty 53
technology fusion 67, 72, 161
technology market power 34, 82
technology motivated M&As compared to market-motivated M&As 87
economies of scope 35
and M&A motivations 30, 32–3
effect of M&As on R&D ex post 51, 52–3, 58, 61
measurement of impact of M&As on R&D ex post 54
effect on R&D 34, 65, 161
R&D effort 122, 123
R&D outputs 48, 59
R&D performance 34, 135–6, 161
in R&D process empirical study 83–4, 87, 100–102, 108–9, 111, 122–3
R&D resource acquisition 32
risk-sharing 22
effect of technological relatedness 34, 52–3, 59–60
technological synergies 48, 148
see also DSM acquisition of Gist-brocades case study
technology sector 16
telecommunications sector 13, 16, 22–4, 32
Telenor 24
Telia 24
time horizons 17, 85, 117, 140, 144, 150
see also product life-cycles
time series 54
top management 51, 58, 139–40, 163
transaction cost reductions 31
transnational cost reductions 22
transport cost reductions 33
United Kingdom 23, 24, 25, 155
USA
anti-trust legislation 11, 12
chemical sector M&As 135
deals 14, 15, 16
deregulation 17
European Union bidders 25, 26
European Union targets 25, 26
impact of M&As on R&D ex post 45, 55–6
impact of R&D intensity on M&As 47–8
M&A relatedness 53
telecommunications sector, European takeovers 23–4
transaction values 14, 15, 16
see also Pharmacia & Upjohn and Monsanto merger case study
validity 79–80
value creation see added value; synergies
value culture 49, 146
vertical mergers 11
vertically-integrated firms 18
vinyl activities of Solvay merger with BASF case study see Solvay and BASF merger case study
Vishny, R. 40
Vitt, J. 2, 49, 50–51, 53, 160
Vodaphone 13, 23
Yin, R. 79